Literature DB >> 21467216

HSV-1 Cgal+ infection promotes quaking RNA binding protein production and induces nuclear-cytoplasmic shuttling of quaking I-5 isoform in human hepatoma cells.

Virginia Sánchez-Quiles1, María I Mora, Victor Segura, Anna Greco, Alberto L Epstein, Maria Giovanna Foschini, Loïc Dayon, Jean-Charles Sanchez, Jesús Prieto, Fernando J Corrales, Enrique Santamaría.   

Abstract

Herpesvirus type 1 (HSV-1) based oncolytic vectors arise as a promising therapeutic alternative for neoplastic diseases including hepatocellular carcinoma. However, the mechanisms mediating the host cell response to such treatments are not completely known. It is well established that HSV-1 infection induces functional and structural alterations in the nucleus of the host cell. In the present work, we have used gel-based and shotgun proteomic strategies to elucidate the signaling pathways impaired in the nucleus of human hepatoma cells (Huh7) upon HSV-1 Cgal(+) infection. Both approaches allowed the identification of differential proteins suggesting impairment of cell functions involved in many aspects of host-virus interaction such as transcription regulation, mRNA processing, and mRNA splicing. Based on our proteomic data and additional functional studies, cellular protein quaking content (QKI) increases 4 hours postinfection (hpi), when viral immediate-early genes such as ICP4 and ICP27 could be also detected. Depletion of QKI expression by small interfering RNA results in reduction of viral immediate-early protein levels, subsequent decrease in early and late viral protein content, and a reduction in the viral yield indicating that QKI directly interferes with viral replication. In particular, HSV-1 Cgal(+) induces a transient increase in quaking I-5 isoform (QKI-5) levels, in parallel with an enhancement of p27(Kip1) protein content. Moreover, immunofluorescence microscopy showed an early nuclear redistribution of QKI-5, shuttling from the nucleus to the cytosol and colocalizing with nectin-1 in cell to cell contact regions at 16-24 hpi. This evidence sheds new light on mechanisms mediating hepatoma cell response to HSV-1 vectors highlighting QKI as a central molecular mediator.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467216      PMCID: PMC3108845          DOI: 10.1074/mcp.M111.009126

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  75 in total

1.  Eclipse phase of herpes simplex virus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26.

Authors:  Katinka Döhner; Kerstin Radtke; Simone Schmidt; Beate Sodeik
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Regulation of herpes simplex virus poly (A) site usage and the action of immediate-early protein IE63 in the early-late switch.

Authors:  F McGregor; A Phelan; J Dunlop; J B Clements
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  RNA polymerase II is aberrantly phosphorylated and localized to viral replication compartments following herpes simplex virus infection.

Authors:  S A Rice; M C Long; V Lam; C A Spencer
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

4.  Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect.

Authors:  W R Hardy; R M Sandri-Goldin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors.

Authors:  Pelagia Foka; Aldo Pourchet; Ruben Hernandez-Alcoceba; Polyxeni P Doumba; George Pissas; Vlassis Kouvatsis; Georgia Dalagiorgou; Dorothea Kazazi; Peggy Marconi; Mariagiovanna Foschini; Roberto Manservigi; Manousos M Konstadoulakis; John Koskinas; Alberto L Epstein; Penelope Mavromara
Journal:  J Gene Med       Date:  2010-12       Impact factor: 4.565

6.  Herpes simplex virus type 1 immediate-early protein ICP27 is required for efficient incorporation of ICP0 and ICP4 into virions.

Authors:  Lenka Sedlackova; Stephen A Rice
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

7.  Proteomic analysis of cells in the early stages of herpes simplex virus type-1 infection reveals widespread changes in the host cell proteome.

Authors:  Robin Antrobus; Kyle Grant; Bevin Gangadharan; David Chittenden; Roger D Everett; Nicole Zitzmann; Chris Boutell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

8.  Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene.

Authors:  I H Gelman; S Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.

Authors:  W Cai; P A Schaffer
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Virus-Induced Chaperone-Enriched (VICE) domains function as nuclear protein quality control centers during HSV-1 infection.

Authors:  Christine M Livingston; Marius F Ifrim; Ann E Cowan; Sandra K Weller
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more
  13 in total

Review 1.  Investigating the biology of alpha herpesviruses with MS-based proteomics.

Authors:  Esteban A Engel; Ren Song; Orkide O Koyuncu; Lynn W Enquist
Journal:  Proteomics       Date:  2015-05-15       Impact factor: 3.984

2.  Methylthioadenosine (MTA) Regulates Liver Cells Proteome and Methylproteome: Implications in Liver Biology and Disease.

Authors:  Emilie Bigaud; Fernando J Corrales
Journal:  Mol Cell Proteomics       Date:  2016-01-27       Impact factor: 5.911

3.  The RNA binding protein Quaking represses host interferon response by downregulating MAVS.

Authors:  Kuo-Chieh Liao; Vanessa Chuo; W Samuel Fagg; Shelton S Bradrick; Julien Pompon; Mariano A Garcia-Blanco
Journal:  RNA Biol       Date:  2019-12-19       Impact factor: 4.652

4.  Contribution of MS-Based Proteomics to the Understanding of Herpes Simplex Virus Type 1 Interaction with Host Cells.

Authors:  Enrique Santamaría; Virginia Sánchez-Quiles; Joaquín Fernández-Irigoyen; Fernando Corrales
Journal:  Front Microbiol       Date:  2012-03-20       Impact factor: 5.640

5.  EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.

Authors:  Desamparados Roda; Josefa Castillo; Marcelino Telechea-Fernández; Anabel Gil; Gerardo López-Rodas; Luís Franco; Patricia González-Rodríguez; Susana Roselló; J Alejandro Pérez-Fidalgo; Elena R García-Trevijano; Andrés Cervantes; Rosa Zaragozá
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 6.  Proteomics and integrative omic approaches for understanding host-pathogen interactions and infectious diseases.

Authors:  Pierre M Jean Beltran; Joel D Federspiel; Xinlei Sheng; Ileana M Cristea
Journal:  Mol Syst Biol       Date:  2017-03-27       Impact factor: 11.429

7.  Identification and characterization of host proteins bound to dengue virus 3' UTR reveal an antiviral role for quaking proteins.

Authors:  Kuo-Chieh Liao; Vanessa Chuo; Wy Ching Ng; Suat Peng Neo; Julien Pompon; Jayantha Gunaratne; Eng Eong Ooi; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2018-03-23       Impact factor: 4.942

Review 8.  Bioinformatic Analysis of Temporal and Spatial Proteome Alternations During Infections.

Authors:  Matineh Rahmatbakhsh; Alla Gagarinova; Mohan Babu
Journal:  Front Genet       Date:  2021-07-02       Impact factor: 4.599

9.  Proteomic analysis of purified turkey adenovirus 3 virions.

Authors:  Pankaj Kumar; Jan van den Hurk; Lisanework E Ayalew; Amit Gaba; Suresh K Tikoo
Journal:  Vet Res       Date:  2015-07-09       Impact factor: 3.683

10.  CDK1 and PLK1 coordinate the disassembly and reassembly of the nuclear envelope in vertebrate mitosis.

Authors:  Ines J de Castro; Raquel Sales Gil; Lorena Ligammari; Maria Laura Di Giacinto; Paola Vagnarelli
Journal:  Oncotarget       Date:  2017-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.